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A B S T R A C T
Self-rated health (SRH) is a commonly used health indicator predicting morbidity and mortality in a range of
populations. However, the relationship between SRH and medication is not well established. The aim of this
study was to examine adolescent SRH as a predictor for prescribed medication later in young adulthood.
Eighteen years’ prospective data from the Nord-Trøndelag Health Study (HUNT) and the Norwegian Prescription
Database (NorPD) were analyzed. Baseline data, gathered from 8982 adolescents (mean age 16.0 years) in the
Young-HUNT I survey (1995–1997), were linked to individual data from NorPD, including information on all
medications prescribed in 2013–2014. Gender-stratified negative binomial regression models were used to in-
vestigate the association between SRH and medication, also adjusted for age, baseline self-reported medicine
use, physical and mental disability, smoking, and physical activity. Based on the Anatomical Therapeutic
Chemical (ATC) Classification System, total consumption and consumption related to various ATC groups were
examined.
The adjusted analyses showed a dose–response relationship for females, with poorer SRH predicting higher
average medication for both total consumption and for the ATC groups “Musculoskeletal system” (M), “Nervous
system” (N; Analgesics (N02), Opioids (N02A)) and “Respiratiory system” (R). The predictive power of SRH, as
well as the role of the adjustment factors, varies by gender and drug groups. This knowledge is important in
order to identify risks for later disease and to capture pathological changes before and beyond the disease
diagnosis, potentially preventing morbidity in the adult population.
Self-rated health (SRH or subjective, self-assessed, self-perceived
health) is among the most commonly used indicators of present health
status as seen from the individual’s own perspective (Idler & Benyamini,
1997; Jylhä, 2009). It is commonly measured by a one-item question,
where people are asked to rate their health status on a four- or five-
point scale, from poor to excellent, or to compare their health with that
of age peers (Jylhä, 2009). According to the literature, health is con-
ceptualized during childhood and adolescence (Wade & Vingils, 1999;
Breidablik, Meland & Lydersen, 2008). SRH thereafter seems to also be
a stable construct (Boardman, 2006; Breidablik, Meland & Lydersen,
2009), in one study, over an 11-year period from adolescence to early
adulthood (Vie, Hufthammer, Holmen, Meland & Breidablik, 2014). It
encompasses biological, psychological and social dimensions (Fylkesnes
& Forde, 1991; Manderbacka, 1998).
Several studies have showed that SRH measured by one single
question is a powerful predictor of morbidity and mortality in a range
of populations (Benyamini & Idler, 1999; Idler & Benyamini, 1997;
Shadbolt, Barresi & Craft, 2002). Among adults, SRH has been related to
functional ability (Idler & Kasl, 1995; Idler, Russell & Davis, 2000;
Neufeld, Machacova, Mossey & Luborsky, 2013), health-risk behavior
(Haddock et al., 2006), contact with primary care (Bath, 1999;
Miilunpalo, Vuori, Oja, Pasanen & Urponen, 1997), hospitalization
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(Mutran & Ferraro, 1988; Doiron, Fiebiga, Joharb & Suziedelytec,
2015), and medical outcomes, i.e., diabetes mellitus (Wennberg et al.,
2013) and cardiovascular disease (Møller, Kristensen & Hollnagel,
1996). Individuals reporting poor SRH are worse off than those who
rate their health as good, and the predictive effect of SRH on health
outcomes remains after controlling for both demographic factors and
objective measures of health status (DeSalvo, Bloser, Reynolds, He &
Muntner, 2006; Idler & Benyamini, 1997).
SRH has also been associated both with over-the-counter (OTC)
medications and with prescription drugs. In Europe, in the cross-sec-
tional study among 4824 adolescents, poor SRH predicted more fre-
quent use of OTC medications (Holstein, Hansen, Andersen & Due,
2008), and in a sample of 6702 persons, aged 20–79 years, those who
rated their health as poor were more likely to be daily (versus sporadic)
users of analgesics and drugs against dyspepsia/peptic ulcer (Furu &
Thelle, 2001). In another cross-sectional study amongst 3085 adults in
Bangladesh (where essentially no prescription is needed to purchase
medicine), bad SRH was associated with two times higher medicine
consumption than self-reported “good health” (Haque,Tisha, Mustafa &
Rahman, 2015). A Finnish study of 700 older community-dwelling
people found poor SRH as one of the factors most significantly asso-
ciated with analgesic use (Pokela, Bell, Lihavainen, Sulkava &
Hartikainen, 2010). In a cross-sectional study poor subjective health
also acted as an independent predictor of polypharmacy (five or more
prescribed drugs) among 466 older general practice patients in Ger-
many (Junius-Walker, Theile & Hummers-Pradier, 2007). In a one-year
prospective framework an Australian study (with over 200,000 ob-
servations) self-assessed health indeed predicted future health, as
measured by hospitalizations, out-of-hospital medical services and
prescription drugs (Doiron et al., 2015). In contrast, in a cross sectional
study among 131 Danish schoolchildren maternal health (including
SRH) did not significantly influence child use of OTC analgesics in the
past 3 months (Jensen et al. 2014).
However, there is a lack of prospective studies investigating the
relationship between SRH and medication among younger subjects and
future health (Gobina et al., 2011). As objective health status is also
assumed to influence the person’s subjective rating of their health
(Murata, Kondo, Tamakoshi, Yatsuya & Toyoshima, 2006), longitudinal
studies are needed to confirm the findings and the temporal relation-
ship. Additionally, most current studies on young populations examine
self-reported or OTC medications, whereas few studies examine the link
between SRH and prescribed medication.
Prescribed medication is one of the health care systems’ most im-
portant methods to treat, relieve, and sometimes cure diseases (Skoog,
Midlöv, Borgquist, Sundquist & Halling, 2014), and the majority (over
50%) of medical consultations is found to result in a prescription
(Loikas, Wettermark, von Euler, Bergman & Schenck-Gustafsson, 2013;
Wilson, McDonald, Hayes & Cooney, 1992). In Norway, prescribed
medication accounted for 86% of total number of defined daily doses
(DDD) in 2014, and these fractions have remained relatively constant
over time (Sakshaug, 2016). Further, prescribed medication is an im-
portant objective health indicator, as it is prescribed by a doctor in-
tended to be used by a person in the diagnosis, cure, mitigation,
treatment, or prevention of specific diseases. As the different drug
groups as described by the Anatomical Therapeutic Chemical (ATC)
Classification system (WHO Collaborating Centre for Drug Statistics
Methodology, 2014) reflect different bodily systems (e.g. cardiovas-
cular, musculoskeletal, nervous systems), information regarding the
association between SRH and specific drug groups may give a more
nuanced understanding of the relationship between SRH and specific
health outcomes. Although the associations between SRH and later
morbidity are well documented (Idler & Benyamini, 1997), its me-
chanisms are poorly understood, especially regarding which bodily
systems are involved. A relevant question is whether subjective health
perceptions predict disease from certain bodily systems more than
others.
A theoretical framework that may be used to understand the un-
derlying mechanisms through which SRH results in chronic or “objec-
tive” disease is the conceptual model of allostasis (McEwen & Seeman,
1999). Allostasis is the adaptive regulatory process that maintains
homeostasis during exposure to physical, psychosocial and environ-
mental challenges or stressors (McEwen & Seeman, 1999). Yet, ex-
cessive amounts of such activation may results in allostatic load (AL)
leading to physiological dysregulation, which in turn may increase the
risk of manifest disease in multiple bodily system. In view of this model,
previous research has found poor SRH in adolescence to predict AL 11
years later via mechanisms of sustained activation of multiple bodily
systems, including biomarkers representing the endocrine (HR), meta-
bolic (HDL, triglycerides, diabetes risk profile) and anthropometric
(WHR, BMI) system (Vie, Meland & Breidablik, 2014). In such a view an
examination of the relation between SRH and different drug groups
may increase our understanding of the relation between SRH and dif-
ferent bodily systems. Yet, except from the Australian one-year pro-
spective study (Doiron et al., 2015), the current studies presented
above, do not examine medication from several drug groups at one
time.
The main aim of the present study was to examine to what degree
SRH in adolescence predicts prescribed medication eighteen years later,
in adult age. We examine both total consumption and the following
ATC groups: the “Cardiovascular system”, “Antiinfectives for systemic
use”, the “Musculoskeletal system”, the “Nervous system” and the
“Respiratory system”, thereby also testing if SRH predicts certain
medication group better than others.
Method
Study population
The study is based on the Norwegian Prescription Database (NorPD)
and eighteen years’ prospective data from the Nord-Trøndelag Health
(HUNT) Study. The HUNT Study is a large population-based health
study in the county of Nord-Trøndelag, Norway, based on self-reported
questionnaires, interviews and clinical measurements. The baseline
data for the present study were collected in the Young-HUNT1 survey
(1995–1997), in which 10,202 adolescents (ages 12–20) were invited,
and 8982 (4519 males and 4463 females) completed the questionnaire
(response rate 88%) (Fig. 1). For a detailed description of the sample
and design of the project, see Holmen et al. (2013) and Krokstad et al.
(2013). Questionnaires are available at the HUNT website, https://
www.ntnu.edu/hunt/data/que.
Using the unique 11-digit personal identity number assigned to
every Norwegian citizen at birth, the data from Young-HUNT1, were
accurately linked to individual data from the NorPD prescription da-
tabase at the Norwegian Institute of Public Health (for details regarding
the linkage procedure, see https://www.ntnu.edu/hunt/merging-
registries; see also Holmen et al., 2013; Furu, 2008). The NorPD
monitors drugs dispensed by prescription in Norway and the database
contains a complete listing of all prescription drugs dispensed by
pharmacies since 2004. It captures all prescriptions dispensed at
pharmacies to individual patients in open care, and all pharmacies in
Norway are obliged by law to forward prescription data to the NorPD
(Furu, 2008). As the data are collected from pharmacies, it only cap-
tures prescriptions that are actually dispensed (and not over-the-
counter medication or medication bought abroad). Hence, we only in-
cluded dispensed prescription and the register has 100% coverage. In
the present study, we include information on all prescribed medications
for the years 2013 and 2014 (measured as the number of prescriptions,
as information on defined daily dose (DDD) was frequently not avail-
able) (see also the NorPD website; http://www.norpd.no/).
The Norwegian Health Care system has a universal coverage, with a
small co-payment in primary care (OECD Economic Surveys, 2005).
General practice is the first line of medical healthcare, and is based on a
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Regular General Practitioner Scheme, and a patient list system estab-
lished for the entire population (St.meld. nr. 23, 1996–1997). Hence,
most people who reside in Norway have access to a regular general
practitioner (GP). The GPs are gatekeepers to specialist services and
therefore exert large influence on specialist utilization (St.meld. nr. 23,
1996–1997).
Measures
Self-rated health (SRH) measured in the Young-HUNT1 survey is
based on a four-point ordinal scale answer to the question “How is your
health at the moment?”, with the possible responses “Very good”,
“Good”, “Not so good”, and “Poor”. Since few respondents (0.6%) re-
ported their health as “Poor”, we have grouped them together with the
respondents reporting “Not so good” in the statistical analyses.
Medication
Prescribed medicines recorded in the NorPD are classified according
to the ATC classification system as of 2015 (WHO, 2014). Based on the
ATC system and previous findings linking SRH to different bodily
system (Christian et al. 2011; Doiron et al., 2015; Janszky, Lekander,
Blom, Georgiades & Ahnve, 2005; Pokela et al., 2010; Rogers, Everett,
Saint Onge & Krueger, 2010; van der Linde et al., 2013; Vie et al.,
2014), we define nine drug groups (Table 2), including a group for all
prescriptions excluding contraceptives (G03A and G03B). Quantities of
dispensed drugs are measured in terms of the number of prescriptions
(as DDD information was not available for many of the prescriptions).
Unadjusted and adjusted analyses
We performed separate analyses for males and females, since gender
has been associated with both SRH (Idler, 1993; Idler & Benyamini,
1997; Manderbacka, 1998) and medication (Fernández‐Liz et al.,
2008). Similarly, baseline medicine use (Bertoldi et al. 2012), smoking
(Barendregt, Bonneux, & van der Maas, 1997; Lasser et al. 2000),
physical and mental disability (Doiron et al., 2015), and physical activity
(Dale et al. 2015) have all been associated with subjective health per-
ceptions and may affect the relationship between SRH and medication
by influencing both the independent and dependent variables. Research
has also shown a joint effect of multiple lifestyle behaviors (e.g.,
smoking and physical activity) on health outcomes (Ford, Zhao, Tsai &
Li, 2011). We therefore report the association between SRH and med-
ication adjusted for all these predictors.
In the current study baseline medicine use was based on questions
worded like “Do you take/use any of these medicines or dietary sup-
plements?”, including seven types of medications: pain relievers, mi-
graine medicine, sleep medicine, nerve medicine, relaxants, asthma
medicine, and allergy medicine. Daily use was recorded as “yes” if the
person used at least one of these medicines daily. The question on
physical activity had the response options “yes”, “no” and “no, but used
to participate in physical activity before” (the latter was treated as
“no”). For smoking, there were similar options (“yes” and “no”, but with
some qualifiers, e.g. “no, but earlier I sometimes used to smoke” treated
as no). Physical and mental disability was assessed by asking the parti-
cipants if they had suffered from any long-term illness or injury of a
physical or psychological nature that impaired their functioning in
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Fig. 1. Study population flow chart.
Table 1
Demographic data for adolescents, stratified by self-reported health.
Not so good/poor Good Very good Overall
(n = 968) (n = 5352) (n = 2508) (n = 8828)
Mean/n SD/% Mean/n SD/% Mean/n SD/% Mean/n SD/%
Age 16.2 1.8 16.1 1.8 15.9 1.8 16.0 1.8
Sex, male 437 45% 2498 47% 1506 60% 4441 50%
Daily smoker 314 41% 1066 23% 227 10% 1607 21%
Daily medication 133 17% 409 9% 101 4% 643 8%
Physical disability 187 23% 322 7% 52 2% 561 7%
Mental disability 134 17% 204 4% 38 2% 376 5%
Physically active 314 33% 2588 49% 1708 68% 4610 52%
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adolescents and the included variables, stratified by SRH.
Ethics
All study subjects and the parents or guardians of those under the
age of 16 years gave written consent to participate in the HUNT study
and to the use of data for research. It was informed that participation
was voluntary. The study was approved by the Norwegian Data
Inspectorate, the Regional and National Committees for Medical and
Health Research Ethics and the Norwegian Directorate of Health.
Statistical methods
We report the crude number of prescriptions stratified by SRH as
means with 95% percentile bootstrap confidence intervals (based on
10,000 replications), along with p-values from Welch ANOVA tests
(Welch, 1951). This test was chosen because it is sensitive to differences
in means while being insensitive to differences in variances.
To examine how much a single, coarsely categorized, question on
self-reported health could predict the number of prescriptions, we fitted
count regression models with SRH as a predictor. To assess whether
SRH still had any predictive power on prescription use when including
common (strong) predictors of prescription use, we included age
(continuous), daily use of medication (yes/no), physical disability (yes/
no), mental disability (yes/no), smoking (yes/no), and physical activity
(yes/no) as additional predictors. Initial analyses revealed that Poisson
count models did not fit the data well, because they predicted a smaller
variation in the number of prescriptions than what was observed. To
account for this overdispersion, we therefore fitted negative binomial
regression models. We report the results from the models as ex-
ponentiated coefficients, which estimate the relative increase/decrease
in the mean number of prescriptions for different levels of the pre-
dictors compared to their reference levels. For all models, we used
“good SRH” as the reference level for SRH, since it is the most common
SRH level, i.e. corresponding a “typical” person, and “no” for binary
predictors.
All data analyses were done using R version 3.3.0 (R Core Team
2016). The negative binomial regression models were fitted using the
“glm.nb” function in the “MASS” package (Venables & Ripley 2002).
We examined the models for any problems with multicolinearity, using
the VIF statistic. For all tests, we define statistically significant as having
a P-value ≤ 0.05.
There were little missing data on SRH, and for the main analyses we
therefore only report results on non-missing SRH status. For daily use of
medication, we treat missing responses as “no” daily use. For the other
variables, we use complete-case analysis, and report the number of
observations the analyses are based on.
Results
Descriptive statistics
At baseline (T1), the vast majority (89%) of the respondents rated
their health as “good” (61%) or “very good” (28%), while 11% rated
their health as “not so good” (10%) or “poor” (0,6%). The overall
prevalence of medication use was 9% (males 8%, females 10%). Table 2
shows the average number of prescribed medications, stratified by ATC
group, sex, and SRH.
SRH as a predictor of prescribed medication
Table 3 and Fig. 2a show the results of sex-stratified negative bi-
nomial regression models for SRH in adolescence (T1) as a predictor of
the number of prescribed medication in adult age (T2). For space rea-
sons, we only report the (unadjusted and adjusted) estimated effect of
SRH. There were no problems with multicolinearity, as all VIF values
were<2.
In the unadjusted analyses, for both sexes, SRH in adolescence
predicted total drug consumption in adulthood. The result shows a
dose–response relationship between SRH and medicine use, with poorer
SRH in adolescence predicting higher average medication in adulthood.
Adjusting for age, baseline medicine use, physical activity, smoking,
and mental and physical disability attenuated the effect of SRH on later
medication, and it was no longer statistically significant for men.
More specifically, the adjusted analyses showed a dose–response
relationship, with poor SRH in adolescence predicting higher average
medication for both total consumption and the ATC groups
“Musculoskeletal system” (M), “Nervous system” (N; Analgesics (N02),
“Opioids” (N02A)) and “Respiratory system” (R) for females. For males
there was no statistically significant results for the adjusted analysis.
Hence, prescribed medication for the “Cardiovascular system”;
“Antiinfectives for systemic use”; “Anxiolytics/hypnotics/sedatives”
and “Antipsychotics/antidepressants/psychostimulants” in adult age
were not predicted by adolescence SRH in the adjusted analyses. All the
adjustment variables were associated with later prescriptions, yet in
different degrees, depending on medicine groups and gender. Especially
baseline self-reported medication seems to play an important role as a
predictor (for both genders): Those respondents reporting medicine use
in adolescence were more likely to use prescription drugs in adult age.
For the cardiovascular system, the estimated effects showed do-
se–response relationships for both sexes, but none of the models
achieved statistical significance.
For antiinfectives for systemic use, in the unadjusted analyses, we
found a clear effect for females, but none for males. Adjusting for other
predictors attenuated the estimated predictive effect of SRH.
For the muscolo-skeletal system, the unadjusted models showed
statistically significant effects for both females and males. In the ad-
justed models these effects were attenuated, and for males no longer
significant.
For the analgesics group, there were large effects of SRH for both
females and males. Again, these were attenuated when adjusted for
other predictors (and no longer significant for males).
For the anxiolytics/hypnotics/sedatives group the largest, and only
statistical significant, effect was found for females.
For the opioid group, SRH had a predictive effect in the unadjusted
analyses for both sexes, and for females it remained significant (but
attenuated) after adjustment.
The antipsychotics/antidepressants/psychostimulants group only
showed a predictive effect of SRH for females, and only before adjusting
for other predictors.
The respiration group showed statistically significant effects for
both unadjusted and adjusted analyses for females. For males, the es-
timated effect was much smaller, and significant only in the unadjusted
model.
There was an association between SRH status and having an in-
complete questionnaire (P<0.001), where the people with some
missing data reported worse SRH (17% reporting “poor”/”not so good”
SRH, as compared to 10% for the people with complete data).
Discussion
The aim of the present study was to examine SRH in adolescence as
a predictor of prescribed medication in adulthood, by using 18 years
prospective data from a large population-based sample and register-
based outcomes. More specifically, using the Anatomical Therapeutic
Chemical (ATC) Classification System (WHO Collaborating Centre for
Drug Statistics Methodology, 2014), we aimed to examine adolescence
SRH as a predictor for both total medication consumption and for
medication consumption related to specific ATC groups.
Adjusting for age, smoking, baseline medicine use, physical activity,
and mental and physical disability, the analyses showed a dose–r-
esponse relationship between SRH in adolescence and total
T.L. Vie et al. SSM - Population Health 4 (2018) 144–152
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consumption in young adulthood, with poorer SRH predicting higher
average medication for both total consumption and the ATC groups
“Musculoskeletal system” (M); “Nervous system” (N; Analgesics (N02);
Opioids (N02A)), and “Respiratory system” (R) for females, but not for
males. The predictive power of SRH, as well as the role of the adjust-
ment factors, varied by gender and drug groups.
The finding that adolescent SRH predicted prescribed medication
(both total and with regard to the specific drug groups) in adult age
corresponds with previous research, which has consistently shown SRH
to predict morbidity and mortality (Idler & Benyamini, 1997;
Benyamini & idler, 1999; Shadbolt et al., 2002) and also with a previous
cross-sectional study showing associations between SRH and self-re-
ported medicine use among adolescence (Holstein et al., 2008), and a
one-year prospective study showing subjective health to predict pre-
scribed medication among adults (Doiron et al., 2015). The current
study expands on this, by demonstrating that SRH is also important
with regard to prescribed medication, in a long-term perspective, from
adolescence and eighteen years later to (young) adulthood. This in-
dicates that subjective health perceptions early in life affect long-term
health. Moreover, by demonstrating the association between SRH and
the specific ATC groups across genders, the current findings indicate
some possible psychological and physiological mechanisms (e.g. the
musculoskeletal system and the nervous system), linking SRH in ado-
lescence to future health outcomes.
As expected, the effect of SRH on later medication decreased in the
adjusted analyses. All the adjustment variables were associated with
later prescriptions, yet in different degrees, depending on medicine
groups and gender.
We had some missing data on the other predictors included in the
regression models, and missingness was related to SRH. The effect of
this is that people with poor SRH are underrepresented in our study. As
people with “poor”/”no so good” SRH might be less inclined to com-
plete a large questionnaire, we suspect that of the people actually
analyzed, the ones reported to have the lowest levels of SRH are
somewhat more healthy than the corresponding people in the whole
population.
Several explanations for the association between SHR and later
objective health exist. In line with Idler and Benyamini (1997) one
possible explanation for the current findings is that SRH elicit inclusive
“summary ratings” of health, which likely capture diagnosed diseases,
severity and comorbidity of conditions, but also self-perceived but not-
yet-diagnosable bodily sensations related to disease processes. Second,
SRH ratings are dynamic catching chronic, but also recent or recurrent
health problems that otherwise may be missed during one-time “ob-
jective” evaluations (Idler & Benyamini, 1997). Third, SRH reflects, and
also affects behavioral factors (e.g., smoking and physical activity) and
emotional factors (e.g., depression) (Idler & Benyamini, 1997). Finally,
SRH reflects a person’s perceived resources (e.g., social support) that
may influence later health (Benyamini, 2011). Clearly, the mechanisms
are complex and although existing evidence provides support for each
of these explanations, the actual mechanisms underlying the predictive
validity of SRH in relation to subsequent health remain complex.
The current findings add to the literature by demonstrating that
SRH relates to multiple bodily (both physiological and psychological)
systems. The finding that SRH in adolescence predicted prescribed
medications for the musculoskeletal system (ATC group M) for females
corresponds with Doiron et al. (2015) showing that subjective health
perception had significant effects on drugs and certain out-of-hospital
medical services (by rheumatologists, physiotherapists and podiatrists).
It should be noted that in Norway some painkillers that may be used for
the musculoskeletal system including nonsteroidal anti-inflammatory
drugs (NSAIDs) are available without a prescription. Consequently, our
significant finding regarding SRH as a predictor for medication re-
presenting the musculoskeletal system can be treated as a more “pure”
result, representing the association between SRH and more serious ail-
ments that are associated with the musculoskeletal system.
The current study also shows that SRH in adolescence predicted the
number of prescribed medications for the ATC-group N (nervous
system). More specifically, the finding that SRH in adolescence pre-
dicted later use of analgesics for females supports the cross-sectional
study who found a difference between sporadic and daily users of an-
algesics depending on the extent they rated their health as poor (Furu &
Thelle, 2001). Another one-year prospective study found poor SRH to
be one of the main factors associated with analgesic use (Pokela et al.,
2010). Furthermore, the finding that SRH in adolescence (T1) predicted
prescription for opioids is partly in line with a Danish study showing
that users of opioids clearly had a poorer SRH compared with users of
other drug groups (Rosholm & Christensen, 1997).
Table 2
Average number of prescribed medicines (with 95% confidence intervals) in young adulthood for different levels of SRH status in adolescence.
Group ATC code(s) Sex Not so good / poor Good Very good P-valuea
Total, excl. contraceptives All except G03A Female 14.8 (12.5–17.8) 9.3 (8.7–9.8) 7.6 (6.8–8.7) < .001
and G02B Male 8.9 (6.8–11.7) 6.9 (6.2–7.7) 5.3 (4.6–6.1) 0.001
Cardiovascular system C Female 0.6 (0.3–0.9) 0.2 (0.2–0.3) 0.2 (0.1–0.2) 0.03
Male 0.4 (0.2–0.7) 0.3 (0.2–0.4) 0.2 (0.2 to 0.3) 0.34
Antiinfectives for systemic use J Female 1.4 (1.2–1.6) 1.2 (1.1 to 1.3) 1.0 (0.9–1.1) < .001
Male 0.6 (0.5–0.7) 0.5 (0.5–0.6) 0.6 (0.5–0.6) 0.93
Musculoskeletal system M Female 1.2 (1.0–1.4) 0.8 (0.7–0.9) 0.6 (0.5–0.7) < .001
Male 0.8 (0.6–1.1) 0.6 (0.6–0.7) 0.5 (0.5–0.6) 0.02
Analgesics N02 Female 2.1 (1.6–2.7) 1.2 (1.0–1.4) 0.7 (0.5–1.0) < .001
Male 1.6 (0.8–2.5) 0.8 (0.6–1.0) 0.5 (0.4–0.7) 0.02
Anxiolytics/hypnotics/sedatives N05B, Female 0.7 (0.4–1.1) 0.4 (0.3–0.5) 0.3 (0.1–0.4) 0.04
N05C(A-F) Male 0.6 (0.2–1.2) 0.3 (0.2–0.4) 0.2 (0.–0.4) 0.30
Opioids N02A Female 1.0 (0.7–1.5) 0.6 (0.5–0.8) 0.3 (0.2–0.6) 0.006
Male 1.2 (0.5–2.1) 0.6 (0.4–0.8) 0.4 (0.2–0.5) 0.04
Antipsychotics/antidepressants/psychostimulants N05A, N06A,and N06B Female 1.8 (1.1–2.9) 0.7 (0.6–0.8) 0.6 (0.4–0.8) 0.03
Male 1.1 (0.7–1.5) 0.7 (0.5–0.9) 0.6 (0.3–1.0) 0.28
Respiration R Female 2.2 (1.8–2.6) 1.5 (1.4–1.6) 1.2 (1.0–1.4) < .001
Male 1.3 (1.1–1.6) 1.1 (1.0–1.2) 0.9 (0.8–1.1) 0.01
The medicines are classified according to the ATC classification system as of 2015 (WHO, 2014), in 9 groups, including a group for all prescriptions excluding contraceptives (n = 8828).
Abbreviations: WHO: World Health Organization; ATC: Anatomical Therapeutic Chemical; SRH: Self-rated health.
a Test of difference in mean number of prescribed medicines (Welch ANOVA test).
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Finally, SRH in adolescence (T1) predicted the number of prescribed
medication for respiration among females (and males in the unadjusted
analysis). This finding corresponds with Latham and Peek (2013),
which described significant associations between SRH and subsequent
morbidity in arthritis and lung disease.
However, the predictive effect of SRH on ATC group C (the
Table 3
Estimated predictive effect of SRH in adolescence (HUNT 1,1995–1997) on the number of prescriptions in young adulthood (NorPD, 2013–2014),*.
Sex Group Adjustment** SRH: Not very good / poor SRH: Very good P-valueb
Estimate 95% CI P-valuea Estimate 95% CI P-valuea
Females Total, excl. contraceptives Unadjusted 1.51 1.32 to 1.73 < .001 0.80 0.72 to 0.88 < .001 < .001
Adjusted 1.29 1.12 to 1.48 < .001 0.84 0.76 to 0.94 0.001 < .001
Cardiovascular system Unadjusted 1.49 0.89 to 2.66 0.15 0.75 0.49 to 1.14 0.17 0.08
Adjusted 1.48 0.86 to 2.68 0.18 0.79 0.52 to 1.23 0.28 0.16
Antiinfectives for systemic use Unadjusted 1.21 1.03 to 1.42 0.02 0.86 0.76 to 0.98 0.02 0.001
Adjusted 1.12 0.95 to 1.32 0.18 0.91 0.80 to 1.03 0.12 0.09
Musculoskeletal system Unadjusted 1.47 1.19 to 1.83 < .001 0.72 0.60 to 0.85 < .001 < .001
Adjusted 1.21 0.97 to 1.53 0.10 0.77 0.65 to 0.92 0.004 0.002
Analgesics Unadjusted 1.69 1.25 to 2.32 < .001 0.65 0.51 to 0.82 < .001 < .001
Adjusted 1.33 0.96 to 1.88 0.08 0.69 0.54 to 0.88 0.002 0.001
Anxiolytics/hypnotics/sedatives Unadjusted 1.56 0.90 to 2.88 0.13 0.56 0.37 to 0.88 0.01 0.005
Adjusted 1.15 0.65 to 2.16 0.64 0.62 0.39 to 1.01 0.04 0.12
Opioids Unadjusted 1.46 1.02 to 2.12 0.04 0.55 0.42 to 0.74 < .001 < .001
Adjusted 1.10 0.75 to 1.64 0.64 0.60 0.45 to 0.81 < .001 0.003
Antipsychotics/antidepressants/ Unadjusted 1.99 1.19 to 3.56 0.01 0.78 0.52 to 1.19 0.24 0.006
psychostimulants Adjusted 1.31 0.76 to 2.39 0.35 0.81 0.54 to 1.25 0.32 0.32
Respiration Unadjusted 1.56 1.25 to 1.96 < .001 0.82 0.69 to 0.97 0.02 < .001
Adjusted 1.31 1.05 to 1.66 0.02 0.81 0.68 to 0.96 0.01 < .001
Males Total, excl. contraceptives Unadjusted 1.25 1.05 to 1.51 0.02 0.79 0.71 to 0.88 < .001 < .001
Adjusted 0.96 0.80 to 1.16 0.65 0.90 0.81 to 1.01 0.08 0.22
Cardiovascular system Unadjusted 1.49 0.74 to 3.39 0.29 0.73 0.46 to 1.17 0.18 0.14
Adjusted 1.25 0.61 to 2.85 0.55 0.75 0.46 to 1.22 0.22 0.35
Antiinfectives for systemic use Unadjusted 1.00 0.79 to 1.25 0.98 0.99 0.86 to 1.14 0.90 0.99
Adjusted 0.94 0.74 to 1.18 0.58 1.04 0.90 to 1.20 0.59 0.69
Musculoskeletal system Unadjusted 1.15 0.90 to 1.47 0.27 0.83 0.71 to 0.97 0.02 0.01
Adjusted 1.03 0.80 to 1.32 0.83 0.92 0.78 to 1.08 0.28 0.53
Analgesics Unadjusted 2.07 1.43 to 3.07 < .001 0.62 0.49to0.80 < .001 < .001
Adjusted 1.26 0.85 to 1.92 0.23 0.82 0.64 to 1.05 0.10 0.12
Anxiolytics/hypnotics/sedatives Unadjusted 1.98 0.88 to 5.31 0.13 0.80 0.47 to 1.41 0.43 0.12
Adjusted 0.83 0.36 to 2.18 0.67 0.86 0.51 to 1.45 0.56 0.80
Opioids Unadjusted 2.05 1.34 to 3.28 0.002 0.57 0.43 to 0.77 < .001 < .001
Adjusted 1.19 0.75 to 1.96 0.44 0.81 0.60 to 1.09 0.15 0.26
Antipsychotics/antidepressants/ Unadjusted 1.25 0.59 to 3.07 0.59 1.00 0.62 to 1.66 0.99 0.85
psychostimulants Adjusted 0.94 0.45 to 2.28 0.89 1.37 0.84 to 2.28 0.21 0.42
Respiration Unadjusted 1.19 0.90 to 1.60 0.23 0.84 0.70 to 1.00 0.05 0.03
Adjusted 0.96 0.72 to 1.29 0.78 0.91 0.76 to 1.08 0.29 0.56
Abbreviations: SRH: Self-rated health. CI: Confidence interval.
* Based on negative binomial regression models stratified by sex (n = 4,441 for males and n = 4,387 for females). The reference group is “good” SRH, and the estimates are count
ratios, e.g. an estimate of 1.5 for “not very good / poor” SRH indicates an expected 50% increase in the number of prescriptions as compared to “good” SRH.
** The “adjusted” results are adjusted for age, daily use of medication, physical disability, mental disability, smoking, and physical activity.
a P-values for testing the if the number of prescriptions for the given SRH level differs from the number of prescriptions for the reference SRH level (“good” SRH, representing a
“typical” person).
b P-values for testing the overall effect of SRH level on the number of prescriptions, i.e. if the number of prescriptions vary among the three SRH levels.
Fig. 2. (a). Estimated predictive effect of SRH and
other potential risk factors in adolescence on the
number of prescriptions in young adulthood. The
reference group is “good” SRH, and the estimates are
count ratios, e.g. an estimate of 1.5 for “not very
good / poor” SRH indicates an expected 50% in-
crease in the number of prescriptions as compared to
“good” SRH. The horizontal lines show 95% con-
fidence intervals.
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cardiovascular system) did not achieve statistically significance, in
contrast to previous research, revealing SRH as a strong predictor of
cardiovascular disease (van der Linde et al., 2013). One reason for this
may be our young (30–40 years old) and healthy population, where
medication for cardiovascular disease are not prevalent.
Notably, the current study demonstrated sex differences regarding
the association between SRH and future medication, both with regard
to total consumption, consumption related to the specific ATC groups,
and regarding the adjustment variables. Specifically, the adjusted
analyses show that SRH predict total medicine consumption only
among females. In reference to the specific ATC groups, SRH seem to
influence future medication more broadly among females, as compared
to males. Previous studies have found inconsistencies in sex differences
regarding the predictive ability of SRH on both morbidity and mor-
tality, with some studies demonstrating the relation between SRH and
mortality for females (Halford, Ekselius, Anderzen, Arnetz & Svärdsudd,
2010), whereas in other studies it was demonstrated only for males
(Benyamini & Idler, 1999; Deeg & Kriegsman, 2003). One possible ex-
planation for these gender differences is that the study variables in-
cluded may reflect gender differences it-self as there are significant
differences in both health perceptions and drug prescription between
females and males in Europe and the United States (Skoog et at., 2014).
In general, females assess their health worse than males do (Currie
et al., 2012), tend to have more health complaints, to use more pre-
scription drugs as compared to males (Gobina et al., 2011). Females
may also be more likely to pursue medical services (Jorm, Grayson,
Creasey, Waite & Broe, 2000), increasing their probability of receiving
prescriptions over time (Nordfjærn, Bjerkeset, Moylan, Berk & Gråwe,
2013). Second, the meaning of health and, accordingly, the inter-
pretation of the SRH question may differ between males and females, as
females may put weight on more widespread health problems, while
males may put emphasis on diseases affecting longevity (Idler &
Benyamini, 1997). Females may also base SRH on a wider range of
health-related factors, as compared to males (Benyamini, Leventhal &
Leventhal, 2000; Brunner, 2006). Third, the potential predictors of the
association between SRH and future health may differ between males
and females (Deeg & Kriegsman, 2003). Accordingly, the choice of
predictors to adjust for may result in overestimation of the predictive
ability of SRH in one or both genders.
In sum, the findings that SRHs act as a predictor for several ATC
groups reflects its associations with multiple bodily systems and adds
support to previous research linking SRH to stress theory-based psy-
chobiological mechanisms, as well as multi-morbidity (Mavaddat,
Valderas, van der Linde, Khaw & Kinmonth, 2014). Yet, the findings
that the relative increase/decrease in prescription for different SRH
response varies between medication groups, and further highlights the
biological basis of SRH, suggesting that a limited focus on any one
health domain may limit the ability to understand health outcomes for
which self-rated health is predictive in a long-term perspective
(Perruccio, Katz & Losina, 2012).
Strengths and limitations
To our knowledge, this is the first prospective study of SRH and
prescribed medication that followed the investigated variables from
adolescence to young adulthood. Most previous studies on SRH and
health outcomes have focused on the elderly, and few studies in-
vestigate the relationship between SRH and health-outcomes from
adolescence to adulthood. Further, most of the current research has a
cross-sectional design, and longitudinal studies have been lacking to
confirm the findings and clarify the temporal relationship between SRH
and health-related outcomes. A major strength of this study is that we
investigated SRH and medication by using an eighteen years’ pro-
spective design, allowing us to identify SRH as a protective or risk
factor for ill health and subsequent medication.
The large population-based sample, as well as the high participation
rate, reinforces the validity of the data. Additionally, the use of a
comprehensive national prescription register, reduce selection or in-
formation biases, and minimize risk of errors in measurement of med-
icine use due to underreporting or inadequate recall by respondents.
Yet, lack of information on adherence is a common concern when re-
porting prescription data for medication, as drug dispensed at phar-
macy, but never or irregularly used, cannot be detected. Yet, as medi-
cation in the current study are seen as a measure for health and not
necessarily medication intake, prescribed medication seem to be a valid
measure of health as it is prescribed by a doctor and intended to treat,
relieve, or cure specific diseases.
A further strength is the use of objective data when investigating the
SRH–health relationship, as recommended in the SRH literature (Jylhä,
Volpato & Guralnik, 2006). Furthermore, in contrast to current research
on SRH and medication, we investigated both total and specific drug
consumption, using the ATC classification system, recommended by the
World Health Organization (WHO). However, one drawback is that the
medication data are based on the number of prescriptions. DDD, which
were not available on many of the prescriptions used in the current
study, may be a better measure of medication use, as dose size may say
something about the seriousness of diseases (Rønning, 2001). Yet, we
believe that excluding prescriptions with missing DDD would introduce
more bias than using the number of prescriptions as an aggregate
measure of medicine use would. We also had some missing data on the
other predictors included in the regression models, limiting the gen-
eralizability of the results.
In addition, factors that are unaccounted for in our analyses might
be influencing the association between SRH and health. The lack of
information on socioeconomic differences, for example, could be a
limitation and may influence the results, as it has shown to be an im-
portant predictor of overall health and SRH (Goodman, Huang, Schafer-
Kalkhoff & Adler, 2007). Parental education may also influence SRH
among adolescents (Breidablik, Meland, Holmen & Lydersen, 2010). In
addition, the health care attendance varies with many factors such as
gender, age, SES, self-management etc. (Grasdal & Monstad, 2011;
Vikum, Krokstad & Westin, 2012; Vikum, Johnsen & Krokstad, 2013).
Further, the Young-HUNT Study has high attendance rate among ado-
lescents attending school, while most non-participants were not in
school when the study was conducted. Therefore, non-attending stu-
dents may have more somatic or mental health problems than attending
participants (Holmen et al., 2013). Finally, it should be acknowledged
that both SRH and medicine use, are rather skewed variables, possibly
influencing the findings.
Conclusion
The findings suggest that SRH predicts both mental and physical
future health, as measured by prescribed medication. The predictive
effect of SRH, as well as the influence of the various variables adjusted
for, varies by type of medication and gender. This information may be
used to identify those at risk for future medication and to further un-
derstand the predictive power of SRH. Given that SRH is mainly formed
early in life and also seems to be a stable construct over time, the
finding that SRH may be a marker for subclinical conditions and/or
early morbidity, indicate that prevention and intervention efforts re-
lated to SRH early in life may be critical to promoting and maintaining
health. SRH is also an important indicator of public health, as it reflects
objective health status and can serve as a global measure of health
status in the general population. Further, SRH could be used as a tool in
the Norwegian healthcare system to identify those who are most in
need of their services (Wu et al., 2013).
The unique value of this study is that it measures SRH earlier in life,
which may improve the ability to predict, prevent and manage disease
over a greater portion of the life span, resulting in improved health and
greater efficiencies in delivering effective care. This should be of in-
terest to the health-care community worldwide. In a global health
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perspective, the current findings also contribute to better understanding
of the specific predictive power of this important global measure of
health. Clearly, there remain many unresolved questions about SRH
and medication, not captured in the present study. Large longitudinal
studies with several, and frequent follow-up points and relevant mea-
surements should further explore the short-term dynamics as well as the
long-term medical outcomes of SRH over time. Such knowledge may be
used to identify the risk for later disease and capture pathological
changes before and beyond the disease diagnosis, and as such prevent
morbidity in the adult population.
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